Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17035645 | 0.82 | MMP8 (0.53) | MMP8PKMCYP4F2CYP4A11HTT | |
| SCHEMBL334816 | 0.78 | MMP8 (0.56) | MMP8PKMCYP4F2CYP4A11HTT | |
| SCHEMBL8166608 | 0.78 | MMP8 (0.38) | MMP8PKMCYP4F2CYP4A11HTT | |
| SCHEMBL2555317 | 0.77 | PKM (0.46) | MMP8PKMCYP4F2CYP4A11HTT | |
| SCHEMBL10595927 | 0.77 | PKM (0.40) | MMP8PKMCYP4F2CYP4A11HTT | |
| SCHEMBL27740818 | 0.76 | CTSK (0.34) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL234357 | 0.76 | MEN1 (0.53) | MMP8PKMCYP4F2CYP4A11HTT | |
| SCHEMBL6127085 | 0.76 | ALDH1A1 (0.36) | MEN1KMT2AALDH1A1CYP3A4L3MBTL1 | |
| SCHEMBL23907058 | 0.75 | MMP8 (0.45) | MMP8PKMCYP4F2CYP4A11HTT | |
| SCHEMBL7631636 | 0.75 | MMP8 (0.45) | MMP8PKMCYP4F2CYP4A11HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377700-B2 | Process for the recovery of a boronic acid | BRACCO IMAGING S.P.A. (IT) | 2019-08-13 | — | — | US | disclosed |
| US-20190077745-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING S.P.A. (IT) | 2019-03-14 | — | — | US | disclosed |
| US-20190071392-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING S.P.A. (IT) | 2019-03-07 | — | — | US | disclosed |
| EP-3369724-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | Bracco Imaging SPA (IT) | 2018-09-05 | — | — | EP | disclosed |
| US-9950991-B2 | Process for the preparation of iopamidol | BRACCO IMAGING S.P.A. (IT) | 2018-04-24 | — | — | US | disclosed |
| EP-3066071-B1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING SPA (IT) | 2018-04-18 | — | — | EP | disclosed |
| EP-3066071-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | Bracco Imaging S.p.A (IT) | 2016-09-14 | — | — | EP | disclosed |
| US-20160237026-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING S.P.A. (IT) | 2016-08-18 | — | — | US | disclosed |
| WO-2015067601-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | BRACCO IMAGING SPA (IT) | 2015-05-14 | — | — | WO | disclosed |
| US-8222404-B2 | [1,2,4]Thiadiazin-3-yl acetic acid compound and methods of making the acetic acid compound | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-7834009-B2 | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834009-B2 | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2009152166-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152166-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090062263-A1 | treating hepatitis C virus infections; inhibitor of HCV NS5B polymerase; N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-5-(3-methyl-butyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-1,1-dioxo-1,4-dihydro-1(lambda 6)-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide; coadministering with additional therapeutic agent | ANADYS PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062263-A1 | treating hepatitis C virus infections; inhibitor of HCV NS5B polymerase; N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-5-(3-methyl-butyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-1,1-dioxo-1,4-dihydro-1(lambda 6)-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide; coadministering with additional therapeutic agent | ANADYS PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062263-A1 | treating hepatitis C virus infections; inhibitor of HCV NS5B polymerase; N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-5-(3-methyl-butyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-1,1-dioxo-1,4-dihydro-1(lambda 6)-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide; coadministering with additional therapeutic agent | ANADYS PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062263-A1 | treating hepatitis C virus infections; inhibitor of HCV NS5B polymerase; N-{3-[1-(4-Fluoro-benzyl)-4-hydroxy-5-(3-methyl-butyl)-2-oxo-1,2,5,6-tetrahydro-pyridin-3-yl]-1,1-dioxo-1,4-dihydro-1(lambda 6)-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide; coadministering with additional therapeutic agent | HAVCR2, TPMT, CYP2B6 | MMP8 2564/4885PKM 4004/4885CYP4F2 384/4885 |
| US-20190071392-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | ITPR3, KCNH3, ITPR2 | MMP8 3347/4885PKM 1043/4885CYP4F2 1314/4885 |
| US-10377700-B2 | Process for the recovery of a boronic acid | BRS3, ELOB, SCO2 | MMP8 4781/4885PKM 3276/4885CYP4F2 764/4885 |
| US-20190077745-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | KCNH3, ITPR3, ITPR2 | MMP8 3501/4885PKM 882/4885CYP4F2 1359/4885 |
| US-20160237026-A1 | PROCESS FOR THE PREPARATION OF IOPAMIDOL | ITPR3, KCNH3, ITPR2 | MMP8 3410/4885PKM 1020/4885CYP4F2 1321/4885 |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | CYP2E1, CYP1A1, CYP1B1 | MMP8 4268/4885PKM 4434/4885CYP4F2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.